Lymphocytopenia, or lymphopenia, is the condition of having an abnormally low level of lymphocytes in the blood.
~~~~~~~~~~~~~~~~~~
A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers - Gynecologic Oncology
Publication History
Published online: January 18, 2017
Highlights
- •Combining PARP inhibition with radiation potentiates DNA damage in tumor cells.
- •This effect may be enhanced in those with an underlying DNA damage deficiency.
- •Combining PARP inhibition with radiation can be tolerable.
- •A single response was observed in a platinum-sensitive, BRCA-mutation + patient.
Background
The
combination of low-dose radiation therapy with PARP inhibition enhances
anti-tumor efficacy through potentiating DNA damage. We combined
low-dose fractionated whole abdominal radiation (LDFWAR) with ABT-888 in
patients with peritoneal carcinomatosis with a dose escalation in
ovarian and fallopian cancer patients (OV).
Methods
Patients
were treated with veliparib, 40–400 mg orally BID on days 1–21 of 3
28-day cycles on 6 dose levels. Dose levels 5 and 6 included only OV
patients. LDFWAR consisted of 21.6Gy in 36 fractions, 0.6 Gy twice daily
on days 1 and 5 for weeks 1–3 of each cycle. Circulating tumor material
and quality of life were serially assessed.
Results
32 pts
were treated. Median follow-up was 45 months (10–50). The most common
treatment-related grade 3 and 4 toxicities were lymphopenia (59%),
anemia (9%), thrombocytopenia (12%), neutropenia (6%), leukopenia (6%),
nausea (6%), diarrhea (6%), anorexia (6%), vomiting (6%) and fatigue
(6%). The maximum tolerated dose was determined to be 250 mg PO BID.
Median PFS was 3.6 months and median OS was 9.1 months. In OV patients,
OS was longer for platinum-sensitive patients (10.9 mo) compared to
platinum-resistant patients (5.8 mo). QoL decreased for all groups
during treatment. Germline BRCA status was known for 14/18 patients with
OV cancers, 5 of whom were BRCA mutation carriers. One objective
response (3%) was observed.
Conclusion
ABT-888
plus LDFWAR is tolerable with gastrointestinal symptoms, fatigue and
myelosuppression as the most common toxicities. The single observed
objective response was in a germline BRCA mutated, platinum-sensitive
patient.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.